|
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. |
50.00% |
|
Roles of sildenafil in enhancing drug sensitivity in cancer. |
50.00% |
|
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in |
50.00% |
|
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) |
50.00% |
|
Case report of a pituitary macroadenoma treated with artemether. |
50.00% |
|
Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome: Methodische Mängel |
50.00% |
|
Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase |
50.00% |
|
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. |
50.00% |
|
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. |
50.00% |
|
WITHDRAWN: Ovarian ablation for early breast cancer. |
50.00% |
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
50.00% |
|
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. |
50.00% |
|
Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. |
50.00% |
|
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) |
50.00% |
|
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. |
50.00% |
|
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and |
50.00% |
|
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non |
50.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Glioblastoma Multiforme |
50.00% |
|
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. |
50.00% |
|
Carbon-ion treatment |
50.00% |
|
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe |
50.00% |
|
Role of everolimus in the treatment of renal cell carcinoma. |
50.00% |
|
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. |
50.00% |
|
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. |
50.00% |
|
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. |
50.00% |
|
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal |
50.00% |
|
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
|
An RF hyperthermia electrode which generates no edge effect. |
50.00% |
|
Cancer Prevention |
50.00% |
|
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp |
50.00% |
|
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit |
50.00% |
|
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. |
50.00% |
|
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer |
50.00% |
|
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? |
50.00% |
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
|
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 |
50.00% |
|
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... |
50.00% |
|
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. |
50.00% |
|
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. |
50.00% |
|
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line |
50.00% |
|
Tumoral angiogenesis: review of the literature. |
50.00% |
|
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... |
50.00% |
|
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study |
50.00% |
|
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother |
50.00% |
|
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera |
50.00% |
|
Novel anti-angiogenic therapies for malignant gliomas. |
50.00% |
|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. |
50.00% |
|
Melatonin |
45.00% |
|
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr |
45.00% |
|
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats |
40.00% |
|
Pancreatic cancer stem cells - insights and perspectives. |
40.00% |
|
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. |
40.00% |
|
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. |
40.00% |
|
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. |
40.00% |
|
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. |
40.00% |
|
Serum cytokines in pancreatic cancer: Correlation with outcome |
40.00% |
|
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. |
40.00% |
|
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. |
40.00% |
|
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. |
40.00% |
|
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... |
40.00% |
|
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. |
40.00% |
|
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. |
40.00% |
|
Long term outcomes following surgical resection of myxopapillary ependymomas. |
40.00% |
|
Mistletoe in conventional oncological practice: exemplary cases. |
40.00% |
|
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... |
40.00% |
|
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco |
40.00% |
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat |
40.00% |
|
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. |
40.00% |
|
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. |
40.00% |
|
Ependymoma. |
40.00% |
|
Enhancement of macrophage tumouricidal activity by the alkaloid derivative |
40.00% |
|
Trans Arterial Chemo Embolization(TACE) |
40.00% |
|
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) |
40.00% |
|
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. |
40.00% |
|
Bioavailability of sorafenib tablets administered as a liquid suspension. |
30.00% |
|
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe |
30.00% |
|
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. |
30.00% |
|
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
|
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
|
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. |
30.00% |
|
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... |
30.00% |
|
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the |
30.00% |
|
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of m |
30.00% |
|
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. |
30.00% |
|
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... |
30.00% |
|
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... |
30.00% |
|
Dendritic Cell Therapy |
30.00% |
|
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz |
25.00% |
|
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. |
20.00% |
|
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
|
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm |
20.00% |
|
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) |
20.00% |
|
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. |
20.00% |
|
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. |
10.00% |
|
High Dose Intravenous Vitamin C |
10.00% |
|
Herbal Based Cancer Therapies |
10.00% |
|
Intravenous DMSO – Unsurpassable Results in Clinical Practice |
|
|
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing |
|
|
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ |
|
